Zhang JJ, Yuan C, Dang SC. Targeting methyltransferase-like 5-mediated sphingomyelin metabolism: A novel therapeutic approach in gastric cancer. World J Gastrointest Oncol 2024; 16(10): 4060-4063 [DOI: 10.4251/wjgo.v16.i10.4060]
Corresponding Author of This Article
Sheng-Chun Dang, Doctor, Professor, Surgeon, Department of General Surgery, The Affiliated Hospital of Jiangsu University, No. 438 Jiefang Road, Zhenjiang 212001, Jiangsu Province, China. dscgu@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4060-4063 Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4060
Targeting methyltransferase-like 5-mediated sphingomyelin metabolism: A novel therapeutic approach in gastric cancer
Jin-Juan Zhang, Chang Yuan, Sheng-Chun Dang
Jin-Juan Zhang, Chang Yuan, Sheng-Chun Dang, Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang 212001, Jiangsu Province, China
Co-first authors: Jin-Juan Zhang and Chang Yuan.
Author contributions: Zhang JJ, Yuan C, and Dang SC wrote the manuscript; all authors have read and approved the final manuscript.
Supported byJiangsu Commission of Health, No. LKZ2023012; and Social Development Project of Zhenjiang City, No. SS2023011.
Conflict-of-interest statement: All the authors have no relevant conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sheng-Chun Dang, Doctor, Professor, Surgeon, Department of General Surgery, The Affiliated Hospital of Jiangsu University, No. 438 Jiefang Road, Zhenjiang 212001, Jiangsu Province, China. dscgu@163.com
Received: April 5, 2024 Revised: May 17, 2024 Accepted: June 5, 2024 Published online: October 15, 2024 Processing time: 174 Days and 5.6 Hours
Abstract
Gastric cancer (GC) is a global health problem and a leading cause of cancer-related deaths, with its mortality rate ranking third among all cancers. The etiology and progression of GC are characterized by a complex interplay of genetic and epigenetic changes, which present challenges for its early diagnosis and effective treatment. Elucidating the mechanisms underlying the occurrence and development of GC and identifying novel biomarkers for early detection and prognosis are crucial to improving patient outcomes. This editorial examines the role of methyltransferase-like 5 (METTL5) in the progression of GC through sphingomyelin metabolism by considering an article published by Zhang et al in the World Journal of Gastrointestinal Oncology in 2024, which is entitled “METTL5 promotes GC progression via sphingomyelin metabolism”. These authors investigated the biological behavior of METTL5 in GC by examining its expression patterns, clinical relevance, functional effect, and potential mechanisms, as well as its response to chemotherapy. This editorial provides valuable insights into the role of METTL5 in the progression of GC and its potential as a therapeutic target.
Core Tip: This study comprehensively analyzes the role of methyltransferase-like 5 (METTL5) in the progression of gastric cancer (GC), highlighting its potential as a new therapeutic target and prognostic biomarker. However, further research is needed to fully understand the functional mechanism of METTL5 in GC and translate these insights into clinical applications. Targeting METTL5-mediated sphingomyelin metabolism is a novel therapeutic approach in GC.
